Myotonic Dystrophies: State of the Art of New Therapeutic Developments for the CNS - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Frontiers in Cellular Neuroscience Année : 2017

Myotonic Dystrophies: State of the Art of New Therapeutic Developments for the CNS

Résumé

Myotonic dystrophies are multisystemic diseases characterized not only by muscle and heart dysfunction but also by CNS alteration. They are now recognized as brain diseases affecting newborns and children for myotonic dystrophy type 1 and adults for both myotonic dystrophy type 1 and type 2. In the past two decades, much progress has been made in understanding the mechanisms underlying the DM symptoms allowing development of new molecular therapeutic tools with the ultimate aim of curing the disease. This review describes the state of the art for the characterization of CNS related symptoms, the development of molecular strategies to target the CNS as well as the available tools for screening and testing new possible treatments.
Fichier principal
Vignette du fichier
Gourdon, Meola - 2017 - Myotonic dystrophies State of the art of new therapeutic developments for the CNS.pdf (1.56 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03832511 , version 1 (22-11-2022)

Identifiants

Citer

Genevieve Gourdon, Giovanni Meola. Myotonic Dystrophies: State of the Art of New Therapeutic Developments for the CNS. Frontiers in Cellular Neuroscience, 2017, 11, pp.101. ⟨10.3389/fncel.2017.00101⟩. ⟨hal-03832511⟩
73 Consultations
28 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More